Supports healthy cell growth and improves operational efficiency

Merck has announced the launch of its Ultimus® Single-Use Process Container Film, designed to provide extreme durability and leak resistance for single use assemblies used for bioprocessing liquid applications.

Bag leaks have long been a top pain point for biomanufacturers, with the cost of a single leak ranging from € 45,000 to € 511,000. To protect against such leaks, abrasions, tears, and material fatigue, Ultimus® film is designed with a proprietary woven nylon structure and provides enhanced bag strength, improved durability, and resilience.

"We are committed to providing our customers with solutions that address their challenges in single-use manufacturing," said Darren Verlenden, Head of Process Solutions for the Life Science business sector of Merck. "Our innovative approach of incorporating woven nylon ensures the film’s robustness while providing ease of handling, flexibility, and conformity to a container that single-use processing demands.”

Maintaining the film's integrity is crucial to ensure product quality, sterility, and reliable manufacturing operations in single-use bioprocessing. To achieve this, Ultimus® film has undergone rigorous testing and demonstrated exceptional performance compared to the average results of five other single-use bioprocessing films. This includes 10 times greater abrasion resistance, 2.8 times greater tensile strength, and twice as much puncture strength.

Ultimus® film provides an animal origin free contact resin that demonstrates a low extractable profile and supports healthy cell growth performance. This cutting-edge technology is now available in Mobius®3D process containers, delivering a stronger and more durable solution that improves operational efficiency while minimizing disruptions.

View Product Information

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

Recent news from Merck